BriefingSubscribe
BrieflyToldAbout
Breaking
Health

Lilly and Hims & Hers expand self-pay access to obesity medicines

Eligible patients prescribed Zepbound or Foundayo through Hims & Hers can receive Lilly’s self-pay prices and home delivery.

BrieflyTold Desk · · 1 min brief

Share𝕏WAf
Illustration · BrieflyTold

The brief

  • ■The agreement covers the FDA-approved medicines Zepbound and Foundayo.
  • ■Self-pay pricing starts at $299 a month for Zepbound and $149 for Foundayo.
  • ■A licensed provider must determine that a prescription is appropriate.

Why it matters

The agreement could simplify access for people paying without insurance, although eligibility and a licensed provider’s prescription still apply.

The full story

Eli Lilly and Hims & Hers announced Friday that eligible patients can consult a licensed provider on the Hims & Hers platform and, if prescribed, receive Zepbound or Foundayo through the service. The companies said the medicines can be shipped to patients’ homes.

The agreement uses Lilly’s self-pay pricing, which starts at $299 per month for Zepbound and $149 per month for Foundayo. Both medicines are FDA-approved, and a prescription remains necessary.

Topics

zepbound self pay pricefoundayo self pay pricelilly hims hers agreementobesity medicine home deliveryzepbound telehealth accessfoundayo 149 per month

Sources

  • Eli Lilly and Company
Read the original reporting ↗

More briefs